CRBU, US1420381089

Caribou Biosciences reviews options. Caribou Biosciences stock is valued at USD 55.6 million

Published on 10/21/2026 at 05:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Caribou halted two CAR-T programs and began a review on October 6, 2026. Market value for Caribou Biosciences stock stood at USD 55.6 million.

Strategic review and cash position

Caribou announced a strategic review and two program discontinuations on October 6, 2026.
Second-quarter 2026 revenue was USD 1.50 million, while GAAP net loss reached USD 24.28 million.
Market value for Caribou Biosciences stock stood at USD 55.6 million as of October 20, 2026.

CRBU, US1420381089, Illustration mit AI erstellt.

Caribou Biosciences (ISIN US1420381089) reported USD 113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, as it reviewed its future after ending development plans for two CAR-T programs. In its release dated October 6, 2026, Caribou Biosciences said its board had approved an evaluation of strategic alternatives.

Two programs leave the pipeline

The October 6 decision covered vispa-cel and CB-011, both allogeneic CAR-T candidates. The company also planned workforce and cost reductions, with most of the workforce reduction expected in the fourth quarter of 2026. Wedbush Securities was appointed exclusive financial adviser for the strategic evaluation.

The financing challenge is central to the decision. Caribou said vispa-cel was ready for a pivotal trial and had FDA alignment on the phase 3 design, but the available capital environment made further development difficult.

What does the cash position mean?

Caribou reported USD 1.50 million of revenue and a GAAP net loss of USD 24.28 million for the second quarter of 2026, according to Securities.io. Operating cash flow was negative USD 22.79 million in that quarter. The cash balance therefore sits beside a business that was still consuming capital before restructuring expenses.

Three dates changed the outlook

On August 13, 2026, Caribou reported second-quarter results including USD 1.50 million of revenue. On October 2, 2026, its board approved a restructuring with estimated costs of USD 15 million to USD 19 million. On October 6, 2026, Caribou announced the strategic review, the planned discontinuation of vispa-cel and CB-011, and the USD 113.8 million cash position.

What analysts changed

On October 7, 2026, Yahoo Finance reported that RBC Capital cut its target from USD 10.00 to USD 1.00 and downgraded Caribou from Outperform to Sector Perform. The same report said Leerink cut its target from USD 4.00 to USD 1.00 and moved to Market Perform.

Nasdaq quote and next milestone

The next operational milestone is the planned workforce reduction, which Caribou expects to be mostly complete in the fourth quarter of 2026. The company is also weighing a merger, acquisition, business combination, or transaction involving its assets.

Caribou Biosciences was last at USD 0.52 on Nasdaq on October 20, 2026 at 4:00 p.m. ET. Its market capitalization was USD 55.6 million, while its 52-week range was USD 0.44 to USD 3.54 as of that date.